Über diesen Artikel
Article Category: Forum of Clinical Oncology
Online veröffentlicht: 20. Apr. 2019
Seitenbereich: 1 - 62
DOI: https://doi.org/10.2478/fco-2019-0001
© 2019 published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
j.fco-2019-0001.tab.002.w2aab3b7ab1b6b1ab1c30b9Aa
| mFOLFIRI plus | mFOLFIRI plus | |
|---|---|---|
| Bevacizumab (n=42) | Panitumumab (n=44) | |
| Analyzed | n=31 | n=44 |
| Mean age (range), years | 75 (70-84) | 76 (70-88) |
| ECOG PS 0/1/2 | 39/58/3 | 25/71/4 |
| Male/Female | 81/19 | 73/27 |
| Rectal Cancer | 16 | 25 |
| Primary tumor not resected | 26 | 16 |
| Overall Response Rate (95% CI), % | 41.9 (24.6%-59.3%) | 47.7 (32.9%-62.5%) |
| Stable Disease, % | 38,7 | 15.9 |
| PFS (95% CI), months | 8.6 (7.6-9.6) | 6.1 (3.6-8.7) |
| OS (95% CI), months | 28.8 (16.5-41.1) | 20.9 (11.7-30.1) |
| 1-year survival, % | 77.4 | 68.2 |
| Median Follow up, months | 39.5 | 36.0 |
| Neutropenia | 19.3 | 9.0 |
| Diarrhoea | - | 20.4 |
| Mucositis | - | 2.3 |
| Skin toxicity | - | 4.5 |
| Fatigue | - | 4.5 |
| Bowel perforation | - | 2.3 |
| Paronychia | - | 2.3 |
| Constipation | 3.2 | - |
| Hypertension | 3.2 | - |
j.fco-2019-0001.tab.001.w2aab3b7ab1b6b1ab1c14b9Aa
| All | Frail G8 ≤14 | Fit G8>14 | |
|---|---|---|---|
| N=40 | N=29 | N=11 | |
| Mean ±SD | 76 ± 4.3 | 73 ± 3 | 77 ± 4.3 |
| Men | 25 | 17 | 8 |
| Women | 15 | 12 | 3 |
| 0-1 | 27 | 17 | 10 |
| 2-4 | 13 | 12 | 1 |
| Adjuvant | 7 | 4 | 3 |
| Metastatic | 33 | 25 | 8 |
| No | 18 | 11 | 7 |
| Yes | 21 | 18 | 3 |
| No | 26 | 15 | 11 |
| Yes | 14 | 14 | 0 |